FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321811593> ?p ?o ?g. }

• W2321811593 endingPage "29254" @default.
• W2321811593 startingPage "29245" @default.
• W2321811593 abstract "// Xinpei Yu 1, 5, 8, 9 , Junkui Ai 1 , Liquan Cai 1 , Yifeng Jing 1, 6 , Dan Wang 1 , Jun Dong 1 , Laura E. Pascal 1 , Jian Zhang 7 , Rongcheng Luo 8 , Zhou Wang 1, 2, 3, 4 1 Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, USA 2 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, USA 3 Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, USA 4 University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, USA 5 Department of Geriatrics, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China 6 Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 7 Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, China 8 Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, China 9 Guangdong Provincial Key Laboratory of Geriatric Infection and Organ Function Support and Guangzhou Key Laboratory of Geriatric Infection and Organ Function Support, Guangzhou, China Correspondence to: Zhou Wang, email: wangz2@upmc.edu Rongcheng Luo, email: rongchengluo72@126.com Keywords: prostate cancer, EAF2, ELL, SIAH2, ubiquitination Received: October 06, 2015      Accepted: March 16, 2016      Published: April 05, 2016 ABSTRACT RNA Polymerase II Elongation Factor (ELL)-associated factor 2 (EAF2) is a tumor suppressor frequently down-regulated in human prostate cancer. We previously reported that its binding partner ELL1 can enhance EAF2 protein stability and activity. Here we show that EAF2 can be polyubiquitinated and its degradation blocked by proteasome inhibitor. Co-immunoprecipitation detected EAF2 binding to SIAH2, an E3 ligase, and SIAH2 overexpression enhanced polyubiquitination of EAF2. Co-transfection of EAF2 binding partner ELL1 blocked EAF2 ubiquitination, providing a mechanism for EAF2 stabilization. Finally, EAF2K81R mutant, which exhibits reduced polyubiquitination and increased stability, was more potent than wild-type EAF2 in apoptosis induction. These findings suggest that SIAH2 is an E3 ligase for EAF2 polyubiquitination and ELL1 can enhance EAF2 level and function by blocking its polyubiquitination." @default.
• W2321811593 created "2016-06-24" @default.
• W2321811593 creator A5026768917 @default.
• W2321811593 creator A5037418007 @default.
• W2321811593 creator A5039890596 @default.
• W2321811593 creator A5047186824 @default.
• W2321811593 creator A5053696763 @default.
• W2321811593 creator A5056813172 @default.
• W2321811593 creator A5057209439 @default.
• W2321811593 creator A5058380236 @default.
• W2321811593 creator A5064478020 @default.
• W2321811593 creator A5084918710 @default.
• W2321811593 date "2016-04-05" @default.
• W2321811593 modified "2023-10-14" @default.
• W2321811593 title "Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells" @default.
• W2321811593 cites W1658347783 @default.
• W2321811593 cites W1820093478 @default.
• W2321811593 cites W1968302410 @default.
• W2321811593 cites W2000116033 @default.
• W2321811593 cites W2012920679 @default.
• W2321811593 cites W2021755549 @default.
• W2321811593 cites W2026140625 @default.
• W2321811593 cites W2028880812 @default.
• W2321811593 cites W2037216960 @default.
• W2321811593 cites W2037992174 @default.
• W2321811593 cites W2038847152 @default.
• W2321811593 cites W2043210655 @default.
• W2321811593 cites W2045877221 @default.
• W2321811593 cites W2049947565 @default.
• W2321811593 cites W2056883195 @default.
• W2321811593 cites W2057727344 @default.
• W2321811593 cites W2063345200 @default.
• W2321811593 cites W2072554910 @default.
• W2321811593 cites W2096643907 @default.
• W2321811593 cites W2109496201 @default.
• W2321811593 cites W2139876169 @default.
• W2321811593 cites W2141182368 @default.
• W2321811593 cites W2147917253 @default.
• W2321811593 cites W2151224270 @default.
• W2321811593 cites W2156854438 @default.
• W2321811593 cites W2161817637 @default.
• W2321811593 cites W4237014973 @default.
• W2321811593 cites W4245361947 @default.
• W2321811593 doi "https://doi.org/10.18632/oncotarget.8588" @default.
• W2321811593 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5045393" @default.
• W2321811593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27058417" @default.
• W2321811593 hasPublicationYear "2016" @default.
• W2321811593 type Work @default.
• W2321811593 sameAs 2321811593 @default.
• W2321811593 citedByCount "6" @default.
• W2321811593 countsByYear W23218115932016 @default.
• W2321811593 countsByYear W23218115932018 @default.
• W2321811593 countsByYear W23218115932019 @default.
• W2321811593 countsByYear W23218115932020 @default.
• W2321811593 countsByYear W23218115932021 @default.
• W2321811593 countsByYear W23218115932022 @default.
• W2321811593 crossrefType "journal-article" @default.
• W2321811593 hasAuthorship W2321811593A5026768917 @default.
• W2321811593 hasAuthorship W2321811593A5037418007 @default.
• W2321811593 hasAuthorship W2321811593A5039890596 @default.
• W2321811593 hasAuthorship W2321811593A5047186824 @default.
• W2321811593 hasAuthorship W2321811593A5053696763 @default.
• W2321811593 hasAuthorship W2321811593A5056813172 @default.
• W2321811593 hasAuthorship W2321811593A5057209439 @default.
• W2321811593 hasAuthorship W2321811593A5058380236 @default.
• W2321811593 hasAuthorship W2321811593A5064478020 @default.
• W2321811593 hasAuthorship W2321811593A5084918710 @default.
• W2321811593 hasBestOaLocation W23218115931 @default.
• W2321811593 hasConcept C121608353 @default.
• W2321811593 hasConcept C126322002 @default.
• W2321811593 hasConcept C143998085 @default.
• W2321811593 hasConcept C17744445 @default.
• W2321811593 hasConcept C191935318 @default.
• W2321811593 hasConcept C199539241 @default.
• W2321811593 hasConcept C2780192828 @default.
• W2321811593 hasConcept C502942594 @default.
• W2321811593 hasConcept C71924100 @default.
• W2321811593 hasConcept C74909509 @default.
• W2321811593 hasConceptScore W2321811593C121608353 @default.
• W2321811593 hasConceptScore W2321811593C126322002 @default.
• W2321811593 hasConceptScore W2321811593C143998085 @default.
• W2321811593 hasConceptScore W2321811593C17744445 @default.
• W2321811593 hasConceptScore W2321811593C191935318 @default.
• W2321811593 hasConceptScore W2321811593C199539241 @default.
• W2321811593 hasConceptScore W2321811593C2780192828 @default.
• W2321811593 hasConceptScore W2321811593C502942594 @default.
• W2321811593 hasConceptScore W2321811593C71924100 @default.
• W2321811593 hasConceptScore W2321811593C74909509 @default.
• W2321811593 hasIssue "20" @default.
• W2321811593 hasLocation W23218115931 @default.
• W2321811593 hasLocation W23218115932 @default.
• W2321811593 hasLocation W23218115933 @default.
• W2321811593 hasLocation W23218115934 @default.
• W2321811593 hasOpenAccess W2321811593 @default.
• W2321811593 hasPrimaryLocation W23218115931 @default.
• W2321811593 hasRelatedWork W1980245127 @default.
• W2321811593 hasRelatedWork W2045770655 @default.
• W2321811593 hasRelatedWork W2221425694 @default.

• next